Equibles does not estimate personal net worth.
Get an email with a short summary when Medpace Holdings, Inc. publishes a filing, an earnings call transcript or a press release.
Get MEDP alertsJesse Geiger is recorded as CFO at Medpace Holdings, Inc. (MEDP). Medpace Holdings, Inc. reported in an 8-K filed April 22, 2026 that Jesse Geiger resigned as President, effective May 31, 2026. The proxy statement of Medpace Holdings, Inc. reports total compensation of $2,396,370 for Jesse Geiger in fiscal 2025, including a base salary of $641,667. Disclosed compensation is on record for 9 fiscal years. Jesse Geiger has spoken on 8 earnings calls across 1 company, most recently for Medpace Holdings, Inc. on April 23, 2026. Medpace Holdings, Inc. is classified in the Diagnostics & Research industry within the Healthcare sector. Other leadership on record at Medpace Holdings, Inc. includes August J. Troendle (CEO and Board Member), August Troendle (CEO and Board Member), Jesse J. Geiger (CFO) and 7 others.
“On April 21, 2026, Jesse Geiger notified the Company of his intent to resign as President and that he will retire from the Company effective May 31, 2026.”
“Revenue for the first quarter of 2026 was $706.6 million. which represents a year-over-year increase of 26.5%. Net new business awards entering backlog in the first quarter increased 23.7% from the prior year to $618.4 million, resulting in the 0.88 net book-to-bill.”
“Revenue in the fourth quarter of 2025 was $708.5 million, which represents a year-over-year increase of 32%, and full-year 2025 revenue was $2.53 billion, a 20% increase from 2024.”
“In the second quarter, the business and funding environment remained strong. We continue to see robust RFP flow and our competitive win rate also remained strong.”
“Net new business awards entering backlog in the first quarter increased 44.2% from the prior year to $356.2 million, resulting in a 1.37 net book to bill. Ending backlog as of March 31st was $1.6 billion, an increase of 26.1% from the prior year.”
“Our net new business awards entering backlog in the fourth quarter increased 27.6% from the prior year to $358.6 million, resulting in a 1.38 net book-to-bill.”
Source not stated
Start not stated–2026-05-31
Diagnostics & Research · Healthcare
CFO
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Medpace Holdings, Inc. (MEDP) | President | $641,667 | $2,396,370 |
| 2024 | Medpace Holdings, Inc. (MEDP) | President | $606,667 | $4,709,067 |
| 2023 | Medpace Holdings, Inc. (MEDP) | President | $549,250 | $945,078 |
| 2022 | Medpace Holdings, Inc. (MEDP) | President | $509,167 | $1,083,377 |
| 2021 | Medpace Holdings, Inc. (MEDP) | President | $466,667 | $2,306,109 |
| 2020 | Medpace Holdings, Inc. (MEDP) | President | $443,442 | $1,880,070 |
| 2019 | Medpace Holdings, Inc. (MEDP) | President | $409,475 | $1,883,882 |
| 2018 | Medpace Holdings, Inc. (MEDP) | Chief Financial Officer and Chief Operating Officer, Laboratory Operations | $400,267 | $676,538 |
| 2017 | Medpace Holdings, Inc. (MEDP) | Chief Financial Officer and Chief Operating Officer, Laboratory Operations | $378,000 | $658,000 |
